2024年9月期通期の業績予想については、売上高が前期比28.5%増の8.50億円、営業損失が14.88億円、経常損失が14.75億円、当期純損失14.79億円とする期初計画を据え置いている。Medinet announced its Q3 FY2024 (Oct. 2023 to Jun. 2024) earnings on the 9th. Revenue increased by 19.8% YoY to ¥0.589 billion, operating loss was ¥0.996 billion (compared to a loss of ¥1.046 billion YoY), recurring loss was ¥0.948 billion (compared to a loss of ¥1.043 billion YoY), and net loss for the quarter was ¥0.951 billion (compared to a loss of ¥1.045 billion YoY).
Sales revenue for the cell processing industry increased by 19.9% YoY to ¥0.589 billion, but segment losses were ¥0.245 billion (compared to a loss of ¥0.242 billion YoY) due to increased sales expenses for expanding cell processing outsourcing. Medinet is actively engaged in expanding its three business areas (specific cell processing material manufacturing, CDMO business, and value chain business). In the cumulative Q3 period, sales have increased in the specific cell processing manufacturing business due to recovery in the number of immune cell processing outsourcing cases, price revisions with some transaction partners, and one-time technical transfer fees for manufacturing outsourcing, and in the CDMO business due to price revisions in manufacturing outsourcing fees.
Sales revenue for the regenerative medicine and other product business decreased by 45.2% to ¥0 billion, resulting in a segment loss of ¥0.316 billion (compared to a loss of ¥0.358 billion YoY) due to reduced research and development expenses. Medinet is aiming for early commercialization of regenerative medicine products and is actively engaged in activities that include pipeline acquisitions and expansions and monitoring development trends of such products both domestically and internationally.
With respect to the performance forecast for the full year ending September 2024, we are maintaining our initial plan to set sales revenue at 8.5 billion yen, a 28.5% increase from the previous year, and operating loss, ordinary loss, and net loss for the period at 1.488 billion yen, 1.475 billion yen, and 1.479 billion yen, respectively.